The anti-LILRB1 antibody GHI/75 has shown potential to enhance T cell cytotoxic activity mediated by an [anti-MART-1 × CD3] BiTE molecule by disrupting the interaction of LILRB1 with HLA-G expressed by malignant melanoma cells (102). Here, LILRB1 is linked to melanoma.